

## FondsSpotNews 287/2025

### Fusion von Fonds der SEB Funds AB Luxembourg

SEB hat uns darüber informiert, dass folgende Fonds zum 08.09.2025 fusionieren. Die Anteile des „abgebenden Fonds“ gehen damit in den „aufnehmenden Fonds“ auf. Das Umtauschverhältnis wird von der Fondsgesellschaft vorgegeben und am Fusionstag bekannt gemacht.

Abgebender Fonds	ISIN	Aufnehmender Fonds	ISIN
SEB Concept Biotechnology D (EUR)	LU0118405827	SEB Läkemedelsfond D (EUR)	SE0024788749

Fondsanteile können über die FFB bis zum 25.08.2025 gekauft und zurückgegeben werden.

Bei der Fondsfusion verfahren wir nach dem Vorschlag der Fondsgesellschaft. Bestehende Pläne in den „abgebenden Fonds“ werden automatisch auf den „aufnehmenden Fonds“ umgestellt und dort fortgeführt. Beachten Sie hierbei jedoch eventuell abweichende Anlageschwerpunkte. Soll zur Abdeckung der ursprünglich verfolgten Anlageziele ein anderer Fonds genutzt werden, benötigen wir einen neuen schriftlichen Auftrag.

Wir weisen darauf hin, dass Planausführungen durch Fusions- und Buchungsprozesse ggf. nicht zum festgelegten Plantermin möglich sind. In diesen Fällen wird die Planausführung zum nächstmöglichen Zeitpunkt und zum aktuellen Preis nachgeholt.

Wir weisen darauf hin, dass die Fusion für unsere gemeinsamen Kunden unter Umständen steuerliche Konsequenzen hat. Wir empfehlen den Kunden daher, sich bei ihrem Steuer- bzw. Finanzberater über die steuerlichen Auswirkungen zu informieren.

Kunden des aufnehmenden Fonds werden ebenfalls über die Fusion informiert.

Den dauerhaften Datenträger der Fondsgesellschaft haben wir Ihnen beigelegt.

**Hierbei handelt es sich um ein Schriftstück der Fondsgesellschaft. Der Inhalt des Dokumentes wird von der FFB nicht geprüft.**

Für die Verwahrung und Administration von Anteilen und die Umsetzung von Aufträgen verweisen wir auf unsere allgemeinen Geschäftsbedingungen und unser Preis- und Leistungsverzeichnis.

Freundliche Grüße

Ihre FFB

Kronberg im Taunus, 6. Juni 2025

# Information regarding fund changes

## Luxembourg-domiciled SEB Concept Biotechnology will merge with Swedish-domiciled SEB Läkemedelsfond

*Information for you as a unitholder in the merging fund.*

*No action is required on your part regarding this merger. Neither you, as a client, nor the value of your fund units will be impacted. However, it is important to be aware of the merger.*

We, at SEB Funds AB (the "Management Company"), will merge the Luxembourg-domiciled SEB Concept Biotechnology (the merging fund) with the Swedish-domiciled SEB Läkemedelsfond (the receiving fund). The merger will be effective 8 September 2025.

The merger aims to simplify and streamline the fund offering while enhancing the efficiency of fund management.

The merging fund and the receiving fund are managed by the same investment team within SEB Funds AB. The primary difference between the funds is that the merging fund has a more focused investment universe, specifically targeting the Biotechnology sector, which is a subsector of the broader Healthcare sector targeted by the receiving fund. The merger will increase the assets under management of the receiving fund, enhancing portfolio management efficiency, operational effectiveness, and cost efficiency. This, in turn, will make the fund more appealing to investors.

### How you as an investor are affected

This is a merger by absorption, whereby the merging fund's holdings, including its assets and liabilities, will be transferred to the receiving fund. The merging fund will be dissolved without liquidation.

If you are an investor of the merging fund at the time of the merger, you will instead receive units in the receiving fund and you will be able to exercise your rights in this fund in the same manner as you could in the merging fund. The total value of the new units will correspond to the total value of the units held in the merging fund.

SEB Funds AB will bear all costs associated with legal, advisory, and administrative actions arising from the merger.

The merger will not have any material impact on the receiving fund, which will continue to follow the same investment objectives and strategy as previously. Furthermore, no significant changes will be required to the receiving fund before or after the merger, and the fund's fees will remain unaffected. Accrued income in the merging fund will be carried forward in the receiving fund. Ongoing reporting on the fund will remain unchanged. Swing pricing will not be applicable in the merger.

Minor, non-material portfolio rebalancing may take place prior to the merger in the merging fund and after the merger in the receiving fund, which might incur transaction costs.

The merging fund is structured as an FCP (Fonds Commun de Placement), while the receiving fund is a Swedish UCITS with an equivalent structure under Luxembourg law. Investors receive units by entering into a contract with SEB Funds AB. Both funds have no legal personality, and their management is carried out by SEB Funds AB.

The merging fund is subject to the *taxe d'abonnement* in Luxembourg, while the receiving fund is not subject to any equivalent tax in Sweden.

### Rights and trading information

If you wish to redeem your holdings in the merging fund before the merger takes place, the following timeframe applies:

### Important dates

- **29 August 2025:** The last opportunity to redeem your holdings in the merging fund before the merger, prior to the cut-off time on this date.
- **5 September 2025:** The calculation of the exchange ratio is performed.
- **8 September 2025:** The merger will be implemented.

As usual, no fee will be charged for redemption or sale of fund units. Please note that redemption may have tax implications, and we recommend contacting your adviser for more information.

The merger itself is not expected to have tax consequences for investors; however, we cannot guarantee this. Therefore, we strongly encourage you to seek advice from your financial adviser.

#### Unit classes and ISINs for the merging and receiving funds

Merging fund: SEB Concept Biotechnology	Receiving fund: <b>SEB Läkemedelsfond</b>
<b>C (EUR)</b> <b>LU0385485148</b>	C (EUR), SE0024788731
<b>D (EUR)</b> <b>LU0118405827</b>	D (EUR), SE0024788749
<b>D (USD),</b> <b>LU2553409058</b>	E (USD) SE0024788756
<b>UC (EUR)</b> <b>LU2249630927</b>	F (EUR), SE0024788764
<b>UD (USD)</b> <b>LU2553409132</b>	G (USD), SE0024788772

Further to the merger becoming effective, subscription and redemption requests for investors that have received new units in the receiving fund can be submitted to the central administration, registrar, and transfer agent of the receiving fund as of 8 September 2025, which will be treated in accordance with the rules for subscriptions and redemptions applicable to the receiving fund.

#### Additional information

The merger has been approved by the Luxembourg financial regulator – CSSF and the Swedish financial regulator – Finansinspektionen.

Product documentation for SEB Concept Biotechnology is available at [www.sebgroup.lu/funds](http://www.sebgroup.lu/funds) (in English), and product documentation for SEB Läkemedelsfond is available (in Swedish) at [www.seb.se/fonder](http://www.seb.se/fonder).

The depositary statement and the approved statutory auditor report regarding the merger for the merging fund, will be available, free of charge, on request from our registered office, SEB Funds AB, Luxembourg branch.

We strongly recommend that you carefully read the Key Information Document (KID) of SEB Läkemedelsfond, which is available in English and attached at the end of the article where this notice appears. A summarised comparison of the funds is provided below.

Sincerely,

SEB Funds AB, Luxembourg Branch

### Detailed comparison of the different features of the merging fund and the receiving fund

This table aims to help investors understand the similarities and differences between the funds being merged. The information in the table is taken directly from the funds' key information documents (KID) and prospectuses.

Product Features	SEB Concept Biotechnology (Merging fund)	SEB Läkemedelsfond (Receiving fund)
<b>Regulatory status</b>	Authorised as UCITS by the CSSF	Authorised as UCITS by FI
<b>Legal structure</b>	Established as a "Fonds Commun de Placement" (FCP).	The receiving fund is structured with an equivalent structure as a "Fonds Commun de Placement" (FCP).
<b>Business Day</b>	Any day on which banks are open for business in Luxembourg, except 24 December and 31 December.	Any Swedish banking day
<b>Valuation Day</b>	A day on which the NAV per Unit is determined or calculated. Unless there is a suspension in the processing of the Fund unit transactions, any bank business day in Luxembourg except 24 December and 31 December.	The day on which the NAV per Unit is calculated, which is on any Swedish banking day.
<b>Investment Objective</b>	The Fund aims to increase the value of your investment over time by outperforming the benchmark. We make active investment decisions, based on analysis and selection, to invest globally, primarily in companies in the biotech sector.	The fund aims to increase the value of unitholders' investment over time and to outperform its benchmark.
<b>Investment Policy</b>	<p>The investment process is fundamentally driven and based on analysis of the companies' business models, earning capacity, management team and market position.</p> <p>We compare the fund's return to the Nasdaq Biotechnology Index, a reinvesting US stock index for the biotechnology sector. The majority of the fund's holdings are constituents of the benchmark, but they differ in weight. The Fund's investment strategy does not aim to restrict how much the Fund's holdings deviate from its benchmark. Deviation, measured as tracking error, will likely be medium compared to other equity funds. The main categories of financial instruments are equities and equity related instruments.</p> <p>The net assets are invested in securities in accordance with the principle of risk diversification, with investments being made primarily in shares, share certificates, convertible bonds and other equity-like securities. The Fund</p>	<p>The fund is an equity fund with focus on equities and equity-related transferable securities of pharmaceutical, biotechnology, medical services, and medical technology companies, as well as firms operating in the healthcare sector. The fund's benchmark is the MSCI World Health Care Net Return Index, a reinvesting global equity index composed of companies within the healthcare industry.</p> <p>The fund's assets are invested in transferable securities in the form of equities and equity-related instruments. Additionally, the fund may invest in other transferable securities, money market instruments, derivatives, and on account with credit institutions. It may also invest up to 10% of its value in other Swedish or foreign UCITS. The fund may also hold the liquid assets necessary for its management.</p> <p>The fund may invest in transferable securities and money market instruments as referred to in Chapter 5, Section 5 of the Swedish UCITS Act.</p> <p>Derivative instruments may be used as part of the investment policy. The fund may also use OTC derivatives. When investing in derivative instruments, the underlying assets must</p>

	<p>will continuously invest at least 51% of its net assets in equity assets as defined in sec. 2 para 8 German Investment Tax Act (2018) and therefore ensure eligibility for the partial tax exemption for equity funds for German resident investors. The Fund may therefore invest up to 49% of its assets in different other transferable securities, subject to complying with the investment restrictions provided for under the Law. Investment in dividend right certificates and participation certificates of companies is permitted, provided they are considered securities under the statutory provisions and restrictions, as outlined in the Management Regulations.</p> <p>In addition to investment in shares, convertible bonds and bonds with warrants to subscribe to transferable securities may also be acquired for the Fund.</p> <p>The issuers of these securities are primarily companies from around the world that operate in the field of biotechnology.</p> <p>The Fund may also invest in interest-bearing securities (including zero coupon bonds), and in regularly traded money market instruments, including liquid assets, as provided for hereafter. In exceptional circumstances, liquid assets may also account for an amount exceeding the net assets of the Fund if and insofar as this is deemed to be in the Unitholders' interests.</p> <p>For treasury purposes the Fund may invest in bank certificates of deposit, banker's acceptances, treasury bills, commercial paper, and other money market instruments, on an ancillary basis and if it is in the best interest of the Unitholders.</p> <p>The Fund may hold ancillary liquid assets. Ancillary liquid assets, or cash on sight, is limited to a maximum amount of 20 % of the Fund's net assets. The full limit of 20% is rarely used and may only be exceeded in situations where exceptional unfavorable market circumstances apply such as September 11 attacks or</p>	<p>consist of or relate to assets referred to in Chapter 5, Section 12 of the Swedish UCITS Act.</p>
--	--	--

	<p>the bankruptcy of Lehman Brothers in 2008.</p> <p>Furthermore, the Management Company may use derivative financial instruments, as provided for hereafter, to ensure efficient portfolio management (including carrying out transactions for hedging purposes) and in order to achieve the investment objective. The Fund may under no circumstances deviate from the stipulated investment objectives when making use of derivatives.</p> <p>The Fund will not invest more than 10% of its net assets in units / shares of other UCITS or UCIs. Within the limits laid down in article 41 (1) (e) of the Law, and unless expressly stated otherwise, such other UCITS or UCIs might have different investment strategies or restrictions than those set forth in this supplement, to the extent that such investments do not result in a circumvention of the investment strategies or restrictions of the Fund.</p> <p>Fund may invest in instruments issued in another currency than the Base Currency of the Fund. The currency exposure of such instruments may be hedged. In case the currency hedging is applicable, it will be specified in the Prospectus Considering the practical challenges of doing so, the Management Company does not guarantee how successful such hedging will be. For more details, see Section 4.2. "Risk Factors" and in particular the paragraph "Hedging risk".</p> <p>The Management Company ensures that the Fund managed by it comply with the ethical and/or sustainability principles that the Management Company follows. Investors should note that the criteria for ethical and sustainable funds are subject to change. Investors can read more about the sustainability principles the Management Company follows on the Website of the Branch.</p>	
<b>Risk management method</b>	Commitment method	Commitment method
<b>Base Currency</b>	EUR	SEK

<b>Summary risk indicator (SRI) set out in the KID</b>	5	4
<b>SFDR category</b>	Article 8 product. The fund promotes environmental, social and governance (ESG) factors and it has a minimum proportion of 10.00% of sustainable with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy investments.	Article 8 product. The fund promotes Environmental/Social (E/S) characteristics, and it has a minimum proportion of 20.00% of sustainable investments with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy; with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy; and with a social objective.
<b>Benchmark</b>	Nasdaq Biotechnology Index	MSCI World Health Care Net Return Index
<b>Unit Classes</b>	UC(EUR) C(EUR) D(EUR) D(USD) UD(USD)	F(EUR) Acc Inst (new) C(EUR) Acc (new) D(EUR) Inc (new) E(USD) Inc (new) G(USD) Inc Inst (new)
<b>Initial min. subscription amount</b>	No	No
<b>Cut-off time for the fund's transfer agent BNYM for subscription, redemption, and conversion requests</b>	15:30 (CET) on a Valuation Day	15:30 CET on any Swedish banking day
<b>Eligible investors</b>	Retail and institutional investor	Retail and institutional investor
<b>Management Company</b>	SEB Funds AB	SEB Funds AB
<b>Depository</b>	Skandinaviska Enskilda Banken AB (publ), Luxembourg branch	Skandinaviska Enskilda Banken AB (publ), Stockholm
<b>Global Distributor</b>	SEB Asset Management AB	SEB Asset Management AB
<b>Administrator</b>	The Bank of New York Mellon SA/NV (Luxembourg branch)	The Bank of New York Mellon SA/NV (Luxembourg branch)
<b>Auditor</b>	Ernst & Young Luxembourg S.A.	Ernst & Young AB
<b>Max. management fee (p.a.)</b>	UC(EUR): 0.75% C(EUR): 1.5% D(EUR): 1.5% D(USD): 1.50% UD (USD): 0.75%	F(EUR) Acc Inst (new): 0.75% C(EUR) Acc (new): 1.5% D(EUR) Inc (new): 1.5% E(USD) Inc (new): 1.5% G(USD) Inc Inst (new): 0.75%
<b>Ongoing cost as per the KID</b>	UC(EUR): 0.94% C(EUR): 1.69% D(EUR): 1.69% D(USD): 1.71% UD (USD): 0.96%	F(EUR) Acc Inst (new): 0.98% C(EUR) Acc (new): 1.73% D(EUR) Inc (new): 1.73% E(USD) Inc (new): 1.73% G(USD) Inc Inst (new): 0.93%
<b>Performance fee</b>	N/A	N/A
<b>Max. subscription fee</b>	N/A	N/A
<b>Redemption fee</b>	N/A	N/A
<b>Conversion fee</b>	N/A	N/A
<b>Taxe d'abonnement (subscription tax) (p.a.)</b>	Unit classes reserved for institutional investors: 0.01%. All other unit classes: 0.05%.	N/A